DPYD IVS14+1 G>A Polymorphism in Colorectal Cancer in Western India

Authors:

Gajjar KK¹, Kobawala TP¹, Vora HH², Trivedi TI³ and Ghosh NR¹*

DOI: 10.23880/oajco-16000109

Volume 1, Issue 2

Abstract

5-fluorouracil (5-FU) is the foundational anticancer drug used today in the treatment of colorectal cancer (CRC). Dihydropyrimidine dehydrogenase (DPYD) acts as a rate-limiting enzyme in the catabolism of 5-FU. Many reports documented that DPYD IVS14+1 G>A polymorphism has been associated with severe 5-FU toxicity. In present study, we aimed to examine the frequency of DPYD IVS14+1 G>A polymorphism in CRC patients in Western region of India. This polymorphism was examined by PCR-RFLP in 143 CRC patients as well as 25 healthy individuals. All CRC patients and healthy individuals showed 100% frequency of wild type G/G genotypes for DPYD IVS14+1 G>A polymorphism. Thus, the heterozygous variant G/A or homozygous variant A/A genotypes were not prevalent in this population. In nut shell, the study revealed the non-occurrence of variant G/A and A/A genotypes for DPYD IVS 14+1 G>A polymorphism in CRC patients as well as healthy individuals in Western region of India.

Keywords:

5-fluorouracil; Colorectal cancer; DPYD IVS14+1 G>A polymorphism; PCR-RFLP

View PDF